KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Non-cash Items (2016 - 2018)

Biomarin Pharmaceutical's Non-cash Items history spans 9 years, with the latest figure at $183.1 million for Q4 2018.

  • For the quarter ending Q4 2018, Non-cash Items fell 34.88% year-over-year to $183.1 million, compared with a TTM value of $183.1 million through Dec 2018, down 34.88%, and an annual FY2018 reading of $183.1 million, up 2655.31% over the prior year.
  • Non-cash Items for Q4 2018 was $183.1 million at Biomarin Pharmaceutical, down from $281.1 million in the prior quarter.
  • The five-year high for Non-cash Items was $630.9 million in Q4 2015, with the low at $183.1 million in Q4 2018.
  • Average Non-cash Items over 5 years is $399.9 million, with a median of $304.4 million recorded in 2016.
  • Year-over-year, Non-cash Items grew 25.65% in 2014 and then tumbled 51.76% in 2016.
  • Tracing BMRN's Non-cash Items over 5 years: stood at $600.1 million in 2014, then increased by 5.14% to $630.9 million in 2015, then plummeted by 51.76% to $304.4 million in 2016, then fell by 7.63% to $281.1 million in 2017, then tumbled by 34.88% to $183.1 million in 2018.
  • Per Business Quant, the three most recent readings for BMRN's Non-cash Items are $183.1 million (Q4 2018), $281.1 million (Q4 2017), and $304.4 million (Q4 2016).